STAT+: What to know about Biogen’s big lupus study readout
The looming readout from the TOPAZ-1 and TOPAZ-2 studies is an important test of the R&D revamp and growth strategy that Biogen CEO Chris Viehbacher implemented when he joined the company in 2022.
Key points
- This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter.
- Continue to STAT+ to read the full story….
- The drug was dapirolizumab and the outcome was positive, in case you were wondering.
More than two years have passed since Biogen announced results from a Phase 3 study in lupus.
In the first half of December, Biogen will hope for a repeat, and once again, it’s another lupus drug, litifilimab, that is being evaluated in twin Phase 3 studies.
Additional details
- Sign up here to get it delivered to your inbox.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.